Tapentadol Consilient Health 50 mg
Immediate-release opioid analgesic for moderate to severe acute pain
Tapentadol Consilient Health 50 mg is a strong, centrally acting opioid analgesic in immediate-release film-coated tablet form, used for the short-term relief of moderate to severe acute pain in adults when non-opioid analgesics such as paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) are insufficient. Tapentadol is distinguished by its unique dual mechanism — combining mu-opioid receptor agonism with norepinephrine reuptake inhibition — and is classified under ATC code N02AX06. This medication is prescription-only and a controlled substance, requiring careful medical supervision due to the risk of addiction, respiratory depression, and serious drug interactions.
Quick Facts
Key Takeaways
- Tapentadol Consilient Health 50 mg is an immediate-release opioid analgesic prescribed for short-term relief of moderate to severe acute pain when non-opioid painkillers are not adequate.
- It has a unique dual mechanism of action (mu-opioid receptor agonism combined with norepinephrine reuptake inhibition), which may provide effective analgesia with potentially fewer gastrointestinal side effects than traditional pure mu-opioid agonists.
- The standard adult starting dose is 50 mg every 4 to 6 hours as needed. The maximum daily dose is typically 700 mg on day one and 600 mg thereafter; doses above this have not been studied and are not recommended.
- Common side effects include nausea, vomiting, dizziness, drowsiness, and constipation. Serious risks include respiratory depression, addiction, seizures, and serotonin syndrome.
- Do not combine tapentadol with MAO inhibitors, alcohol, benzodiazepines, or other CNS depressants without close medical supervision — these combinations can be fatal.
What Is Tapentadol Consilient Health and What Is It Used For?
Tapentadol Consilient Health contains the active substance tapentadol (as tapentadol hydrochloride). Tapentadol is a member of the opioid analgesic class, but it is pharmacologically distinct from traditional opioids such as morphine, oxycodone, or codeine. Its defining feature is a dual mechanism of action often abbreviated as MOR-NRI: mu-opioid receptor agonism combined with norepinephrine reuptake inhibition. This means that tapentadol acts simultaneously on two independent but complementary pain-modulating pathways in the central nervous system.
The first mechanism — mu-opioid receptor agonism — is the classical opioid effect. By binding to and activating mu-opioid receptors in the brain and spinal cord, tapentadol dampens the transmission and perception of pain signals. The second mechanism — norepinephrine reuptake inhibition — enhances the activity of descending inhibitory pain pathways that originate in the brainstem and project down to the spinal cord. These descending pathways use norepinephrine (noradrenaline) as a neurotransmitter to suppress incoming pain signals. By preventing the reuptake of norepinephrine, tapentadol strengthens this endogenous pain-control system. The combination of these two mechanisms in a single molecule may explain why clinical studies suggest tapentadol provides effective analgesia with a somewhat more favorable gastrointestinal tolerability profile than pure mu-opioid agonists at equianalgesic doses.
Unlike extended-release (depot) tapentadol preparations, which are formulated for around-the-clock pain relief in chronic pain conditions, the immediate-release 50 mg film-coated tablet is specifically designed for acute pain that requires a rapid onset and flexible, as-needed dosing. Onset of analgesia typically begins within approximately 30 minutes of oral administration, peak plasma concentrations are reached around 1.25 hours after dosing, and the analgesic effect generally lasts about 4 to 6 hours, which determines the usual dosing interval.
Typical clinical indications for which immediate-release tapentadol may be prescribed include:
- Post-operative pain: Acute pain following surgery, particularly when non-opioid regimens are insufficient.
- Post-traumatic pain: Pain from injuries, fractures, or musculoskeletal trauma.
- Acute flares of chronic pain: Breakthrough pain in patients who need rapid, short-term analgesia.
- Dental pain: Severe odontogenic pain unresponsive to standard analgesics.
- Other acute moderate-to-severe pain that cannot be adequately managed with non-opioid options.
It is important to understand that tapentadol is reserved for pain that is genuinely moderate to severe and that has not responded sufficiently to non-opioid analgesics. It should not be used for mild pain, for long-standing chronic pain without specialist review, or as a first-line analgesic. In keeping with modern opioid stewardship principles, treatment should be limited to the lowest effective dose for the shortest clinically necessary duration. The prescribing physician will have judged that the benefits of opioid therapy outweigh the known risks in your individual clinical situation.
Tapentadol Consilient Health is manufactured and distributed by Consilient Health Ltd., an Ireland-based specialty pharmaceutical company. It is available as 50 mg film-coated tablets intended for oral administration.
What Should You Know Before Taking Tapentadol Consilient Health?
Before starting Tapentadol Consilient Health, your doctor will review your full medical history, current medications, and any risk factors for opioid-related complications. Provide honest and complete information about any previous or current use of alcohol, prescription medications, and illicit substances, as well as any mental health conditions. This information is essential for safe prescribing and does not result in judgment — it allows your doctor to tailor therapy appropriately.
Contraindications
You must not take Tapentadol Consilient Health if any of the following apply to you:
- Hypersensitivity to tapentadol or to any of the excipients listed in the product information.
- Conditions where mu-opioid receptor agonists are contraindicated: including significant respiratory depression and acute or severe bronchial asthma or hypercapnia in unmonitored settings or in the absence of resuscitative equipment.
- Known or suspected paralytic ileus. Opioids further slow bowel motility and can precipitate life-threatening complications.
- Acute intoxication with alcohol, hypnotics, centrally acting analgesics, or psychotropic medicines (drugs affecting mood, mental function, or behavior). The combined CNS-depressant effect can be lethal.
- Concurrent use of monoamine oxidase (MAO) inhibitors or use within the last 14 days. This combination can precipitate serotonin syndrome, severe hypertensive crisis, and cardiovascular collapse.
- Severe hepatic impairment (Child-Pugh class C). Tapentadol is extensively metabolized in the liver and should not be used in patients with severe hepatic impairment.
- Severe renal impairment. The safety and efficacy of tapentadol have not been established in this population.
- Paediatric use. The immediate-release film-coated formulation is not recommended in children and adolescents under 18 years.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Tapentadol Consilient Health if any of the following apply:
- Respiratory conditions: Slow or shallow breathing, chronic obstructive pulmonary disease (COPD), cor pulmonale, sleep apnea, obesity-hypoventilation syndrome, or any condition that compromises respiratory reserve. Tapentadol can cause life-threatening respiratory depression, particularly in elderly or debilitated patients, at initiation of therapy, and with dose increases.
- Head injury or raised intracranial pressure: Tapentadol may obscure the clinical picture in patients with head injuries and can contribute to increases in intracranial pressure. Use with caution and close clinical monitoring.
- Hepatic impairment: Patients with moderate hepatic impairment (Child-Pugh class B) require careful dose titration and longer dosing intervals. Severe hepatic impairment is a contraindication.
- Renal impairment: No dose adjustment is generally required for mild or moderate renal impairment, but caution is advised. Severe renal impairment is a contraindication.
- Biliary or pancreatic disease: Opioids, including tapentadol, can cause spasm of the sphincter of Oddi and may worsen pancreatitis or biliary obstruction.
- Seizure disorders or epilepsy: Tapentadol may lower the seizure threshold, particularly when combined with other medications that also lower the seizure threshold (some antidepressants, antipsychotics, bupropion).
- Mental health conditions: Depression, anxiety, post-traumatic stress disorder, and personality disorders may complicate opioid therapy and increase the risk of misuse. Discuss your psychiatric history openly with your prescriber.
- History of substance use disorder: Personal or family history of alcohol, prescription, or illicit drug misuse is a significant risk factor for opioid addiction. This does not necessarily preclude treatment but warrants closer monitoring and, in some cases, specialist pain-medicine input.
- Elderly patients: Older adults are more sensitive to opioid side effects, particularly sedation, confusion, and respiratory depression. Lower starting doses may be appropriate.
Tapentadol is a Schedule II controlled substance in the United States and is similarly regulated in most other countries. Repeated use, even at prescribed doses, can lead to tolerance (needing higher doses for the same effect), physical dependence (withdrawal symptoms if stopped abruptly), and addiction (compulsive use despite harm). Addiction can occur even in patients receiving appropriately prescribed doses. If you notice increasing urges to take the medication, craving, or difficulty controlling use, contact your doctor promptly. Do not stop abruptly on your own.
Opioids, including tapentadol, can cause central sleep apnea and sleep-related hypoxemia (low oxygen during sleep). Warning signs include witnessed pauses in breathing during sleep, loud snoring, morning headaches, and excessive daytime sleepiness. If you or your bed partner notice these symptoms, contact your doctor, who may consider dose reduction or review of therapy.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking Tapentadol Consilient Health.
- Pregnancy: Tapentadol should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus and no safer alternative is available. Prolonged use during pregnancy can cause neonatal opioid withdrawal syndrome (NOWS), which can be life-threatening to the newborn if not recognized and treated promptly. Symptoms in the newborn include irritability, hyperactivity, abnormal sleep patterns, high-pitched crying, tremor, vomiting, diarrhea, and failure to gain weight.
- Labor and delivery: Tapentadol is not recommended during childbirth. It may cause respiratory depression in the newborn.
- Breastfeeding: Tapentadol and its metabolites may pass into human breast milk. Because of the potential for serious adverse reactions in nursing infants, including respiratory depression, breastfeeding is not recommended during treatment with tapentadol.
Driving and Operating Machinery
Tapentadol can significantly impair reaction time, cognitive processing, and motor coordination through its effects on the central nervous system. Common effects include drowsiness, dizziness, blurred vision, and impaired attention. These effects are most pronounced at the start of treatment, following dose increases, with changes in formulation, and when combined with alcohol or sedative medications. Do not drive, operate heavy machinery, or perform any activities requiring full alertness until you know how tapentadol affects you. In many jurisdictions, driving under the influence of prescribed opioids may still constitute a legal offense if driving ability is impaired.
How Does Tapentadol Consilient Health Interact with Other Drugs?
Drug interactions with tapentadol can be dangerous and sometimes fatal. The dual mechanism of action (mu-opioid agonism and norepinephrine reuptake inhibition) creates interaction potential with a broader range of medications than traditional pure-opioid analgesics. Review your complete medication list with your prescriber before starting treatment, including prescription drugs, over-the-counter preparations, vitamins, and herbal supplements such as St. John's Wort.
Major Interactions (Potentially Life-Threatening)
| Drug / Drug Class | Risk | Recommendation |
|---|---|---|
| MAO inhibitors (phenelzine, tranylcypromine, selegiline, moclobemide, linezolid, methylene blue) | Serotonin syndrome, hypertensive crisis, cardiovascular collapse | Absolutely contraindicated. Do not use during or within 14 days of MAO inhibitor therapy. |
| Benzodiazepines and Z-drugs (diazepam, lorazepam, alprazolam, zolpidem, zopiclone) | Profound sedation, respiratory depression, coma, death | Avoid combination. Reserve for patients in whom alternatives are inadequate; use lowest effective doses for shortest duration. |
| Other opioids (morphine, oxycodone, codeine, tramadol, fentanyl) | Additive respiratory depression, overdose, unpredictable analgesic response | Generally avoid. Careful dose adjustment and monitoring if combination is unavoidable. |
| Alcohol | Enhanced CNS depression, respiratory depression, fatal overdose | Absolute avoidance during treatment. |
| Serotonergic drugs (SSRIs, SNRIs, tricyclic antidepressants, triptans, St. John's Wort, lithium) | Serotonin syndrome — agitation, hyperthermia, myoclonus, autonomic instability | Use with extreme caution. Monitor for signs of serotonin syndrome. Avoid if possible. |
| Gabapentinoids (gabapentin, pregabalin) | Increased risk of opioid-related overdose, respiratory depression, death | Use lowest effective doses with close monitoring. Regulatory agencies have issued specific warnings about this combination. |
| Mixed agonists/antagonists (pentazocine, nalbuphine, butorphanol) or partial agonists (buprenorphine) | Reduced analgesic efficacy; potential precipitated opioid withdrawal | Avoid combination. May diminish tapentadol's analgesic effect. |
Moderate Interactions
| Drug / Drug Class | Risk | Recommendation |
|---|---|---|
| Sedating antihistamines (diphenhydramine, promethazine, hydroxyzine, chlorphenamine) | Additive sedation and respiratory depression | Use with caution. Monitor for excessive sedation. |
| Barbiturates (phenobarbital, thiopental) | Additive CNS depression; phenobarbital may also induce tapentadol metabolism | Avoid if possible; dose adjustment may be needed. |
| Antipsychotics (haloperidol, olanzapine, quetiapine, risperidone) | Additive sedation; may lower seizure threshold | Monitor closely; be alert for seizures and sedation. |
| Muscle relaxants (baclofen, cyclobenzaprine, carisoprodol) | Enhanced sedation and respiratory depression | Use the lowest effective doses; avoid the combination if possible. |
| Strong enzyme inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort) | Reduced tapentadol plasma concentrations and efficacy | Inform your doctor; dose adjustment may be required. |
| Drugs lowering seizure threshold (bupropion, certain antidepressants, antipsychotics, quinolone antibiotics) | Increased risk of seizures | Use with caution, particularly in patients with a history of seizures. |
When combining tapentadol with serotonergic medications, be alert for the symptoms of serotonin syndrome: agitation, confusion, involuntary muscle contractions, tremor, hyperreflexia, excessive sweating, shivering, diarrhea, rapid heart rate, and body temperature above 38°C (100.4°F). Serotonin syndrome is uncommon but potentially life-threatening. Seek immediate medical attention if these symptoms develop.
Always inform your healthcare team about every medication you are taking, including prescription drugs, over-the-counter medicines (such as cold remedies that may contain sedating antihistamines or dextromethorphan), vitamins, minerals, and herbal supplements. Some seemingly innocuous over-the-counter or natural products can have serious interactions with tapentadol.
What Is the Correct Dosage of Tapentadol Consilient Health?
Tapentadol Consilient Health should always be taken exactly as prescribed. The prescribing physician will individualize your dose based on pain severity, prior analgesic experience, age, coexisting medical conditions, and concurrent medications. The guiding principle in modern opioid prescribing is to use the lowest effective dose for the shortest clinically necessary duration.
Adults
Standard Adult Dosing
- Starting dose: 50 mg tapentadol orally every 4 to 6 hours as needed for pain.
- Titration: On the first day of therapy, if adequate pain relief is not achieved within 1 hour of the first 50 mg dose, an additional 50 mg dose may be given. The daily dose on day one should not generally exceed 700 mg.
- Maintenance: Subsequent daily doses should not exceed 600 mg per day.
- Duration: Immediate-release tapentadol is intended for short-term management of acute pain. Reassessment should occur regularly; if ongoing pain requires prolonged opioid therapy, switching to an extended-release formulation or a different approach should be considered by a specialist.
- Do not adjust your own dose. If the tablets seem too strong or too weak, consult your prescriber.
Children and Adolescents
Paediatric Use
- Tapentadol Consilient Health 50 mg immediate-release film-coated tablets are not recommended for use in children and adolescents under 18 years of age.
- The safety and efficacy of this particular immediate-release formulation in this age group have not been established.
- Other tapentadol products (such as specific extended-release or oral solution formulations) may be approved for pediatric use in some jurisdictions; follow the specific product information for each formulation.
Elderly Patients
Elderly Dosing (65 years and older)
- In general, no specific dose adjustment is required in otherwise healthy elderly patients.
- However, older adults are more sensitive to opioid-related sedation, confusion, orthostatic hypotension, and respiratory depression. Consider starting at the lower end of the dosing range.
- Elderly patients more commonly have reduced hepatic and renal function, polypharmacy, and concurrent CNS-acting medications — all of which increase the risk of adverse effects.
- Falls risk is increased with opioid therapy in the elderly. Monitor closely for dizziness and sedation.
Patients with Organ Impairment
| Condition | Recommendation |
|---|---|
| Mild hepatic impairment (Child-Pugh A) | No dose adjustment necessary. |
| Moderate hepatic impairment (Child-Pugh B) | Start at lowest dose (50 mg) with extended dosing interval; careful individual titration. |
| Severe hepatic impairment (Child-Pugh C) | Do not use — contraindicated. |
| Mild/moderate renal impairment | No dose adjustment necessary. |
| Severe renal impairment (CrCl < 30 mL/min or dialysis) | Do not use — safety and efficacy not established. |
How to Take the Tablets
Tapentadol Consilient Health is taken orally (by mouth). Follow these important instructions:
- Swallow the tablet whole with a sufficient amount of water or other liquid.
- The tablets can be taken with or without food — food does not meaningfully affect absorption.
- Do not take doses closer together than every 4 hours. If pain breaks through before the next scheduled dose, contact your doctor rather than increasing the dose on your own.
- Use a pain diary if helpful, recording pain intensity, dose taken, time, and any side effects. This helps your doctor fine-tune therapy.
Missed Dose
Because immediate-release tapentadol is typically taken on an "as-needed" basis for pain, the concept of a missed dose is different from fixed-schedule medications. If your doctor has prescribed it on a regular schedule and you miss a dose, take it as soon as you remember — unless it is almost time for your next dose, in which case skip the missed dose and continue with your usual schedule. Do not take a double dose to make up for the missed one.
Overdose
If you (or someone else) have taken too much Tapentadol Consilient Health, or if a child has accidentally ingested the medication, seek emergency medical help immediately. Call your local emergency number or poison control center without delay.
Symptoms of opioid overdose may include:
- Pinpoint pupils (miosis)
- Extreme drowsiness progressing to unconsciousness
- Cold, clammy, or bluish skin (cyanosis)
- Slow, shallow, or absent breathing (respiratory depression or arrest)
- Vomiting — with risk of aspiration in an unconscious patient
- Slow heart rate (bradycardia) and low blood pressure (hypotension)
- Seizures
- Collapse and coma
Respiratory depression is the leading cause of death in opioid overdose. The opioid antagonist naloxone can reverse respiratory depression caused by tapentadol; however, because the duration of action of naloxone is often shorter than that of the opioid, repeat doses or continuous infusion may be required, and emergency medical supervision is essential. Patients at higher risk of overdose, or those living with them, may be prescribed take-home naloxone as a safety precaution.
Stopping Treatment
Short-term use of tapentadol for acute pain should be stopped as soon as pain resolves. If you have used the medication for only a few days, stopping is usually straightforward and withdrawal is unlikely. However, after prolonged or higher-dose use, abrupt discontinuation can precipitate opioid withdrawal, characterized by:
- Restlessness, anxiety, irritability, and insomnia
- Yawning, watering eyes, runny nose, sneezing, sweating, and chills
- Muscle aches, joint pain, back pain, and tremors
- Abdominal cramps, nausea, vomiting, and diarrhea
- Dilated pupils, increased heart rate, and increased blood pressure
Your doctor will advise on whether tapering is needed and will construct a gradual dose-reduction schedule tailored to your dose and duration of use. Do not attempt to stop abruptly without medical guidance after prolonged use.
What Are the Side Effects of Tapentadol Consilient Health?
Like all medicines, Tapentadol Consilient Health can cause side effects, although not every person experiences them. The profile reflects its opioid mechanism together with noradrenergic effects. Many common adverse effects — particularly nausea and drowsiness — often diminish within the first few days as tolerance develops. Constipation, however, typically does not resolve and may need preventive treatment with stool softeners or laxatives.
Severe allergic reactions (angioedema with swelling of the face, lips, tongue, or throat; difficulty breathing; widespread urticaria), breathing that is slower or shallower than normal, severe drowsiness or unresponsiveness, seizures, or the signs of serotonin syndrome (agitation, high fever, rapid heart rate, muscle twitching). These require emergency evaluation.
Very Common
May affect more than 1 in 10 people
- Nausea
- Vomiting
- Dizziness
- Drowsiness (somnolence)
- Headache
- Constipation
Common
May affect up to 1 in 10 people
- Decreased appetite
- Anxiety, depressed mood, sleep disturbance, nervousness, restlessness
- Attention disturbance, tremor, involuntary muscle twitching
- Flushing, shortness of breath
- Diarrhea, dyspepsia (indigestion), dry mouth
- Itching (pruritus), excessive sweating, skin rash
- Fatigue, asthenia (weakness), feeling of altered body temperature
- Fluid retention (peripheral edema)
Uncommon
May affect up to 1 in 100 people
- Hypersensitivity reactions (including urticaria, pruritus, angioedema; rarely anaphylaxis)
- Weight loss, disorientation, confusion, agitation, perception disturbances
- Abnormal dreams, euphoric mood, drug dependence
- Reduced consciousness, impaired memory, cognitive impairment
- Syncope (fainting), sedation, coordination problems, dysarthria (speech difficulty)
- Paresthesia (numbness, tingling), hypoesthesia (reduced sensation)
- Visual disturbances, increased or decreased heart rate, palpitations
- Decreased blood pressure (including orthostatic hypotension)
- Abdominal discomfort, urinary retention, frequent urination
- Sexual dysfunction, drug withdrawal symptoms, feeling abnormal
Rare
May affect up to 1 in 1,000 people
- Serious drug dependence and addiction
- Abnormal thinking, hallucinations
- Seizures (convulsions)
- Pre-syncope (feeling faint), abnormal coordination
- Respiratory depression (dangerously slow or shallow breathing)
- Delayed gastric emptying
- Feelings of intoxication, excessive relaxation
- Serotonin syndrome (particularly with concurrent serotonergic agents)
Delirium has been reported, particularly in elderly patients. Patients with chronic pain may have an increased baseline risk of suicidal thoughts and behavior; while there is no clear evidence that tapentadol itself increases suicidality, any new or worsening mood symptoms should be reported to your doctor. Adrenal insufficiency and androgen deficiency have been reported with long-term opioid use.
If you experience any side effects, including those not listed above, discuss them with your doctor or pharmacist. Post-marketing surveillance (adverse-event reporting) is important for continued monitoring of the benefit-risk balance of all medicines. You can report suspected adverse reactions through your national pharmacovigilance authority (for example, the MHRA Yellow Card scheme in the UK, the FDA MedWatch program in the United States, or EudraVigilance in the European Union).
How Should You Store Tapentadol Consilient Health?
Proper storage of opioid medications is critically important for safety, particularly in households with children, adolescents, or individuals at risk of substance misuse. Tapentadol is a controlled substance and is a target for diversion; secure storage protects both household members and the wider community.
- Keep out of the sight and reach of children. A single accidental tablet can cause fatal respiratory depression in a child.
- Consider storing the medication in a locked cabinet or lockbox, especially in households where visitors or family members may have a history of substance misuse.
- Store at room temperature (below 25°C / 77°F). No special refrigeration is required. Keep in the original container to protect against moisture and light.
- Do not use the medicine after the expiry date printed on the packaging (after "EXP"). The expiry date refers to the last day of that month.
- Do not use the medicine if the tablets appear damaged, discolored, or if the packaging seal has been compromised.
- Disposal: Do not flush unused tablets down the toilet or throw them in household waste. Return unused medication to your pharmacy for safe disposal through an approved take-back program. This protects the environment and prevents accidental exposure or diversion.
If you have leftover medication after your pain has resolved, dispose of it promptly. Keeping unused opioids in the home is one of the leading contributors to accidental ingestion in children, adolescent experimentation with prescription drugs, and diversion for non-medical use. Many pharmacies, hospitals, and local authorities operate take-back programs precisely for this purpose.
What Does Tapentadol Consilient Health Contain?
Active Ingredient
Each Tapentadol Consilient Health film-coated tablet contains tapentadol hydrochloride equivalent to 50 mg of tapentadol as the base. Tapentadol is a white to slightly off-white crystalline powder that is freely soluble in water.
Inactive Ingredients (Excipients)
The typical inactive ingredients in immediate-release tapentadol film-coated tablets include:
Tablet core: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone, magnesium stearate, and colloidal anhydrous silicon dioxide (colloidal silica).
Film coating: polyvinyl alcohol, titanium dioxide (E171), macrogol (polyethylene glycol), talc, and pharmaceutical-grade iron oxide pigments for color coding.
Tapentadol Consilient Health contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars (e.g., lactose intolerance, galactose intolerance, or glucose-galactose malabsorption), consult your doctor before taking this medicine. Always refer to the current patient information leaflet supplied with the medication for the complete and up-to-date excipient list.
Tablet Appearance and Pack Sizes
Tapentadol Consilient Health 50 mg film-coated tablets are typically supplied as white to off-white, round or oblong film-coated tablets. The tablet may bear a company or product identifier imprint. Specific visual appearance, dimensions, and pack sizes may vary by country and batch — always cross-check with the dispensed product information. Typical pack sizes include blister packs of 10, 20, 30, 50, or 100 tablets.
| Attribute | Details |
|---|---|
| Active ingredient | Tapentadol hydrochloride (equivalent to 50 mg tapentadol) |
| Dosage form | Immediate-release film-coated tablet |
| Route of administration | Oral |
| ATC code | N02AX06 (Other opioids) |
| Marketing authorisation holder | Consilient Health Ltd., Ireland |
| Prescription status | Prescription only (Rx); controlled substance |
Frequently Asked Questions
Tapentadol Consilient Health 50 mg immediate-release film-coated tablets are prescribed for the short-term treatment of moderate to severe acute pain in adults when non-opioid pain medications (such as paracetamol or NSAIDs) are not sufficient. Common clinical contexts include post-operative pain, post-traumatic pain, severe dental pain, and other forms of acute pain that require opioid-level analgesia.
Tapentadol is unique among opioids because it has a dual mechanism of action: it is both a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor (MOR-NRI). Morphine acts almost exclusively on opioid receptors, while tramadol acts on opioid receptors and on both serotonin and norepinephrine reuptake. Because tapentadol does not strongly affect serotonin reuptake, it may have a somewhat lower risk of certain serotonergic interactions than tramadol, though it can still contribute to serotonin syndrome. Additionally, unlike tramadol and codeine, tapentadol does not require bioactivation by the CYP2D6 enzyme, so its analgesic effect is more predictable across individuals with different CYP2D6 genetic variants.
Pain relief typically begins within about 30 minutes of oral administration, with peak plasma concentrations reached at approximately 1.25 hours. The analgesic effect generally lasts 4 to 6 hours, which is why the usual dosing interval is every 4 to 6 hours as needed. Because this is an immediate-release formulation rather than an extended-release one, it acts faster but does not provide continuous 12-hour coverage.
No. Alcohol must be completely avoided during treatment with tapentadol. Alcohol is a central nervous system depressant, and combining it with an opioid dramatically increases the risk of life-threatening respiratory depression, profound sedation, coma, and death. This includes beer, wine, spirits, and alcohol-containing medications or mouthwashes. Even moderate amounts of alcohol can significantly amplify the dangerous effects of opioids.
If you suspect an overdose in yourself or another person, call your local emergency services or poison control center immediately. Warning signs of opioid overdose include pinpoint pupils, extreme drowsiness progressing to unresponsiveness, bluish skin, slow or absent breathing, and collapse. While waiting for emergency help, try to keep the person awake and breathing, and place them in the recovery position if they become unconscious. If naloxone is available at home, administer it according to the label; even after naloxone is given, emergency medical care is essential because naloxone may wear off before the opioid effects.
Tapentadol can cause drowsiness, dizziness, blurred vision, and impaired reaction time — effects that are most pronounced at the start of treatment, after a dose increase, or when combined with alcohol or sedatives. You should not drive, operate heavy machinery, or perform safety-critical tasks until you know how the medicine affects you. In many countries, driving under the influence of an opioid, even when prescribed, may still result in legal consequences if driving ability is impaired. Discuss specifically with your doctor when it is safe for you to resume driving.
Yes. Tapentadol is an opioid and a controlled substance with a recognized risk of addiction, abuse, and physical dependence. Addiction can develop even at prescribed therapeutic doses, although the risk is significantly reduced when the medication is used short-term for acute pain as directed. The risk is higher in people with a personal or family history of substance use disorder, and in those with certain psychiatric conditions. If you notice cravings, difficulty controlling use, or withdrawal-like symptoms between doses, speak with your prescriber promptly.
References
This article is based on the following peer-reviewed and regulatory sources:
- European Medicines Agency (EMA). Tapentadol — Summary of Product Characteristics (SmPC). Available at: ema.europa.eu.
- U.S. Food and Drug Administration (FDA). Nucynta (tapentadol) immediate-release tablets — Prescribing Information. Available at: accessdata.fda.gov.
- World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents (2018). Geneva: WHO.
- Tzschentke TM, Christoph T, Kogel B, et al. “Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.” Drugs of Today. 2009;45(7):483–496.
- Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. “Is tapentadol different from classical opioids? A review of the evidence.” British Journal of Pain. 2016;10(4):217–221.
- Kress HG. “Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally acting analgesics on the horizon?” European Journal of Pain. 2010;14(8):781–783.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022.” MMWR Recomm Rep. 2022;71(No. RR-3):1–95.
- National Institute for Health and Care Excellence (NICE). Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. NICE guideline [NG193]. 2021.
- British National Formulary (BNF). Tapentadol monograph. Available at: bnf.nice.org.uk.
- Riemsma R, Forbes C, Harker J, et al. “Systematic review of tapentadol in chronic severe pain.” Current Medical Research and Opinion. 2011;27(10):1907–1930.
- Raffa RB, Buschmann H, Christoph T, et al. “Mechanistic and functional differentiation of tapentadol and tramadol.” Expert Opinion on Pharmacotherapy. 2012;13(10):1437–1449.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specializing in pain medicine, clinical pharmacology, and evidence-based medicine.
iMedic Medical Editorial Team — specialists in pharmacology and pain medicine with clinical and academic expertise across primary and secondary care.
iMedic Medical Review Board — an independent panel of board-certified physicians who review all content against current international guidelines (EMA, WHO, FDA, NICE, BNF, CDC).
Editorial Standards: All medication information follows the GRADE evidence framework and is cross-referenced with the European Medicines Agency SmPC, FDA Prescribing Information, WHO guidelines, and current peer-reviewed literature. No commercial funding or pharmaceutical sponsorship influences our content. Read more about our editorial standards.